1592U89 data

At the International Conference on AIDS in Vancouver, Glaxo presented preliminary data from a small Phase I/II study of its 1592U89 nucleoside analog reverse transcriptase inhibitor. The trial evaluated the effects of multiple doses of the compound given alone for four weeks, followed by eight weeks in combination with AZT or placebo. The study enrolled 80 patients who were followed for four weeks after the end of therapy.

At four weeks, treatment with 1592U89 at 200 or 400 mg three times daily resulted in a 1.5-2.2 log decrease in the amount of HIV in the blood, and an average increase of 79-127 CD4 cells over baseline. The most frequent side effects were nausea, headache, asthenia and rash. ...